Login / Signup

Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.

Akihiko ShimomuraYasuaki SagaraRyo KotoMasakazu FujiwaraYuka KanemuraHiroshi KitagawaShigehira Saji
Published in: Breast cancer (Tokyo, Japan) (2024)
Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.
Keyphrases